SELLAS Life Sciences (SLS) Share-based Compensation (2010 - 2026)
SELLAS Life Sciences (SLS) reported Share-based Compensation of $798000.0 for Q1 2026, up 58.02% year-over-year from $505000.0 in Q1 2025, and up 78.52% quarter-over-quarter from $447000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Share-based Compensation (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Share-based Compensation data on file, last reported at $798000.0 in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $798000.0, up 58.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 41.18% YoY), and the FY2025 annual result was $2.0 million, up 25.06% from the prior year.
- Share-based Compensation climbed to $798000.0 in Q1 2026 per SLS's latest filing, from $447000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $798000.0 in Q1 2026 and troughed at $334000.0 in Q2 2024.
- A 5-year average of $478705.9 and a median of $476000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation soared 103.8% in 2022, then sank 35.02% in 2024.
- A 5-year view of Share-based Compensation shows it stood at $446000.0 in 2022, then rose by 11.43% to $497000.0 in 2023, then retreated by 24.95% to $373000.0 in 2024, then increased by 19.84% to $447000.0 in 2025, then soared by 78.52% to $798000.0 in 2026.
- Business Quant data shows SLS's Share-based Compensation at $798000.0 in Q1 2026, $447000.0 in Q4 2025, and $503000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | 798,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 798,000.00 |
| Mar 31, 2026 | 798,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Sep 30, 2025 | 503,000.00 |
| Sep 30, 2025 | 503,000.00 |
| Jun 30, 2025 | 501,000.00 |
| Jun 30, 2025 | 501,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Mar 31, 2024 | 476,000.00 |
| Mar 31, 2024 | 476,000.00 |
| Dec 31, 2023 | 497,000.00 |
| Dec 31, 2023 | 497,000.00 |